Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS

주식 순위 #17340
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
주가
$8.16
마지막 동기화: 2025-06-26
시가총액
$234.57M
변동 (1일)
0.00%
변동 (1년)
-56.96%
국가
US
거래 Regulus Therapeutics Inc. (RGLS)

카테고리

Healthcare
Regulus Therapeutics Inc. (RGLS)의 P/S 비율
October 2026 기준 P/S 비율 TTM: 10.69
Regulus Therapeutics Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 10.69입니다. 2022년 말 기준 P/S 비율은 1.64였습니다.
Regulus Therapeutics Inc.의 P/S 비율 기록 (2002 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
2026 (TTM) 10.69 107.09%
2023 5.16 214.26%
2022 1.64 -73.36%
2021 6.16 -33.92%
2020 9.33 -83.36%
2019 56.03 54.87%
2018 36.18 -4.78%
2017 38.00 -28.48%
2016 53.12 122.76%
2015 23.85 -30.11%
2014 34.12 41.52%
2013 24.11 -33.67%
2012 36.35 -50.73%
2011 73.78 -9.84%
2010 81.83 0.48%
2009 81.44 -12.87%
2008 93.48 -5.92%
2007 99.36 -13.68%
2006 115.10 -84.55%
2005 745.11 242.52%
2004 217.54 -23.37%
2003 283.88 2.98%
2002 275.67 0.00%
유사 기업 또는 경쟁사의 P/S 비율
회사 P/S 비율 P/S 비율 차이 국가
10.02 -6.21%
US
40.55 279.49%
US
3.96 -62.93%
AU
- -
CH
10.15 -5.05%
NL